2020 IAS-USA建议：抗逆转录病毒药物预防和治疗成人HIV感染

2020-10-14 国际抗病毒学会-USA JAMA.October 14, 2020.

2020年10月，国际抗病毒学会-USA(IAS-USA)更新发布了抗逆转录病毒药物预防和治疗成人HIV感染建议。本文是对2018版建议的更新，主要针对成人HIV感染的抗逆转录病毒药物预防和治疗提供指

中文标题：

英文标题：

Antiretroviral Drugs for Treatment and Prevention of HIV Infection inAdults 2020 Recommendations of the International Antiviral Society–USA Panel

发布机构：

国际抗病毒学会-USA

发布日期：

2020-10-14

简要介绍：

2020年10月，国际抗病毒学会-USA(IAS-USA)更新发布了抗逆转录病毒药物预防和治疗成人HIV感染建议。本文是对2018版建议的更新，主要针对成人HIV感染的抗逆转录病毒药物预防和治疗提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=5cb281c0019956e4, title=2020 IAS-USA建议：抗逆转录病毒药物预防和治疗成人HIV感染, enTitle=Antiretroviral Drugs for Treatment and Prevention of HIV Infection inAdults 2020 Recommendations of the International Antiviral Society–USA Panel, guiderFrom=JAMA.October 14, 2020., authorId=0, author=, summary=2020年10月，国际抗病毒学会-USA(IAS-USA)更新发布了抗逆转录病毒药物预防和治疗成人HIV感染建议。本文是对2018版建议的更新，主要针对成人HIV感染的抗逆转录病毒药物预防和治疗提供指, cover=https://img.medsci.cn/20201023/1603467998928_2020535.jpg, journalId=0, articlesId=null, associationId=1029, associationName=国际抗病毒学会-USA, associationIntro=null, copyright=0, guiderPublishedTime=Wed Oct 14 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年10月，国际抗病毒学会-USA(IAS-USA)更新发布了抗逆转录病毒药物预防和治疗成人HIV感染建议。本文是对2018版建议的更新，主要针对成人HIV感染的抗逆转录病毒药物预防和治疗提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=8892, tagName=抗逆转录病毒药物)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=8892, guiderKeyword=抗逆转录病毒药物, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3148, appHits=50, showAppHits=0, pcHits=781, showPcHits=3098, likes=0, shares=1, comments=4, approvalStatus=1, publishedTime=Sat Oct 24 00:09:27 CST 2020, publishedTimeString=2020-10-14, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Oct 23 23:47:04 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Thu Jan 04 19:47:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 IAS-USA建议：抗逆转录病毒药物预防和治疗成人HIV感染.pdf)])

2020 IAS-USA建议：抗逆转录病毒药物预防和治疗成人HIV感染.pdf

下载请点击：

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1012123, encodeId=b5c71012123a7, content=赞！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a47a5586944, createdName=ms5000002108221285, createdTime=Fri Aug 27 18:00:01 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977025, encodeId=06c19e7025ba, content=来来来, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:53 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959417, encodeId=405a95941e8a, content=暂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b32b5483913, createdName=ms3000002094955464, createdTime=Thu Apr 22 16:09:38 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898787, encodeId=7496898e87b3, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e95433715, createdName=ms6000001414112870, createdTime=Thu Nov 12 19:52:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
2021-08-27 ms5000002108221285

赞！！！！！！

113 0
[GetPortalCommentsPageByObjectIdResponse(id=1012123, encodeId=b5c71012123a7, content=赞！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a47a5586944, createdName=ms5000002108221285, createdTime=Fri Aug 27 18:00:01 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977025, encodeId=06c19e7025ba, content=来来来, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:53 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959417, encodeId=405a95941e8a, content=暂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b32b5483913, createdName=ms3000002094955464, createdTime=Thu Apr 22 16:09:38 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898787, encodeId=7496898e87b3, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e95433715, createdName=ms6000001414112870, createdTime=Thu Nov 12 19:52:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
2021-06-26 1461bde6m98暂无昵称

来来来

105 0
[GetPortalCommentsPageByObjectIdResponse(id=1012123, encodeId=b5c71012123a7, content=赞！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a47a5586944, createdName=ms5000002108221285, createdTime=Fri Aug 27 18:00:01 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977025, encodeId=06c19e7025ba, content=来来来, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:53 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959417, encodeId=405a95941e8a, content=暂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b32b5483913, createdName=ms3000002094955464, createdTime=Thu Apr 22 16:09:38 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898787, encodeId=7496898e87b3, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e95433715, createdName=ms6000001414112870, createdTime=Thu Nov 12 19:52:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
2021-04-22 ms3000002094955464

暂

121 0
[GetPortalCommentsPageByObjectIdResponse(id=1012123, encodeId=b5c71012123a7, content=赞！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a47a5586944, createdName=ms5000002108221285, createdTime=Fri Aug 27 18:00:01 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977025, encodeId=06c19e7025ba, content=来来来, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:53 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959417, encodeId=405a95941e8a, content=暂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b32b5483913, createdName=ms3000002094955464, createdTime=Thu Apr 22 16:09:38 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898787, encodeId=7496898e87b3, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e95433715, createdName=ms6000001414112870, createdTime=Thu Nov 12 19:52:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
2020-11-12 ms6000001414112870

赞

143 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染指南

2020 IAS-USA建议：抗逆转录病毒药物预防和治疗成人HIV感染

相关指南

拓展阅读

科室

工具

服务